蛋白质组学与孟德尔随机化识别心衰治疗靶点
研究基于4项人群研究共3019名参与者(732例心衰事件)分析90种心血管蛋白与心衰的关联,并对心衰相关蛋白进行孟德尔随机化分析。发现44种蛋白与心衰风险相关,其中8种有因果证据,7种具可成药性,包括肾上腺髓质素等。
要点
- 44种循环蛋白与心衰发生相关,8种有因果证据。
- CSF-1、Gal-3和KIM-1升高增加心衰风险。
- ADM、CHI3L1、CTSL1、FGF-23和MMP-12升高具保护效应。
核心结论
- 鉴定出44种与心衰发生相关的循环蛋白,其中8种有因果关联证据,7种可成药。
研究设计与样本
- 对4项人群研究共3019名参与者(732例心衰事件)进行固定效应荟萃分析,评估90种心血管蛋白与心衰的关联。
主要发现
- 90种蛋白中44种与心衰风险正相关(P<6.0×10-4)。
- 8种蛋白对多重灵敏度分析稳健:CSF-1、Gal-3和KIM-1升高与心衰风险正相关;ADM、CHI3L1、CTSL1、FGF-23和MMP-12升高具保护作用。
关键数值与推荐
- ADM和Gal-3靶向治疗正在临床试验中评估;除KIM-1外,其余蛋白均被认为可成药。
临床怎么用
- 肾上腺髓质素(ADM)是特别有前景的药物靶点,可优先考虑相关药物开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) is a highly prevalent disorder for which disease mechanisms are incompletely understood. The discovery of disease-associated proteins with causal genetic evidence provides an opportunity to identify new therapeutic targets. METHODS: We investigated the observational and causal associations of 90 cardiovascular proteins, which were measured using affinity-based proteomic assays. First, we estimated the associations of 90 cardiovascular proteins with incident heart failure by means of a fixed-effect meta-analysis of 4 population-based studies, composed of a total of 3019 participants with 732 HF events. The causal effects of HF-associated proteins were then investigated by Mendelian randomization, using cis-protein quantitative loci genetic instruments identified from genomewide association studies in more than 30 000 individuals. To improve the precision of causal estimates, we implemented an Mendelian randomization model that accounted for linkage disequilibrium between instruments and tested the robustness of causal estimates through a multiverse sensitivity analysis that included up to 120 combinations of instrument selection parameters and Mendelian randomization models per protein. The druggability of candidate proteins was surveyed, and mechanism of action and potential on-target side effects were explored with cross-trait Mendelian randomization analysis. RESULTS: Forty-four of ninety proteins were positively associated with risk of incident HF (P<6.0×10-4). Among these, 8 proteins had evidence of a causal association with HF that was robust to multiverse sensitivity analysis: higher CSF-1 (macrophage colony-stimulating factor 1), Gal-3 (galectin-3) and KIM-1 (kidney injury molecule 1) were positively associated with risk of HF, whereas higher ADM (adrenomedullin), CHI3L1 (chitinase-3-like protein 1), CTSL1 (cathepsin L1), FGF-23 (fibroblast growth factor 23), and MMP-12 (matrix metalloproteinase-12) were protective. Therapeutics targeting ADM and Gal-3 are currently under evaluation in clinical trials, and all the remaining proteins were considered druggable, except KIM-1. CONCLUSIONS: We identified 44 circulating proteins that were associated with incident HF, of which 8 showed evidence of a causal relationship and 7 were druggable, including adrenomedullin, which represents a particularly promising drug target. Our approach demonstrates a tractable roadmap for the triangulation of population genomic and proteomic data for the prioritization of therapeutic targets for complex human diseases.
引用
- Henry, Gordillo-Marañón, Finan, et al. Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation. 2022. PMID: 35300523. doi:10.1161/CIRCULATIONAHA.121.056663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。